AbSci - About the company
AbSci is a public company based in Vancouver (United States), founded in 2011 by Sean McClain. It operates as a Developer of AI based technology for the production of recombinant protein for therapeutic applications. AbSci has raised $228M in funding from investors like Casdin Capital, AGC and Phoenix Venture Partners. The company has 22 active competitors, including 13 funded and 2 that have exited. Its top competitors include companies like Antiverse, Adimab and Chai Discovery.
Company Details
Developer of AI based technology for the production of recombinant protein for therapeutic applications. The company's integrated drug creation platform enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
- Website
- absci.com
- Social
- Email ID
- *****@abscibio.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2011
Location
Vancouver, United States
Stage
Public
Total Funding
$228M in 7 rounds
Latest Funding Round
Investors
Ranked
6th among 22 active competitors
Annual Revenue
$2.8M as on Dec 31, 2025
Employee Count
173 as on Apr 30, 2026
Exit Details
Public
Legal entities associated with AbSci
AbSci is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ABSCI CORP CIN: 1672688 , United States, Active | Oct 04, 2020 | $2.8M (As on Dec 31, 2025) | - | - |
Absci, Llc CIN: 453931977 , United States, Active | $1M - $5M (As on Dec 18, 2019) | 57 (As on Dec 31, 2020) | - | |
Absci Corporation CIN: 6940491 , United States, Active | Jul 18, 2023 | - | - | - |
Absci Corporation CIN: 853383487 , United States, Active | Dec 31, 1999 | - | 139 (As on Dec 31, 2024) | - |
AbSci's IPO details
AbSci got listed on Jul 22, 2021.
Click here to take a look at AbSci's IPO in detail
Sign up to download AbSci's company profile
AbSci's funding and investors
AbSci has raised a total funding of $228M over 7 rounds. Its first funding round was on Apr 11, 2016. Its latest funding round was a Series E round on Mar 23, 2021 for $*****. 7 investors participated in its latest round. AbSci has 24 institutional investors.
Here is the list of recent funding rounds of AbSci:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 23, 2021 | 4796706 | Series E | 1014491 | 5446568 | 4045566 | 4956930 |
Oct 20, 2020 | 8167057 | Series E | 8471864 | 3008397 | 4614867 | |
Jan 13, 2020 | 8340680 | Conventional Debt | 4676053 | 7760098 | 7812136 | 6894240 |
Access funding benchmarks and valuations. Sign up today!View details of AbSci's funding rounds and investors
AbSci's founders and board of directors
Founder? Claim ProfileThe founders of AbSci is Sean McClain. Sean McClain is the CEO of AbSci.
Here are the details of AbSci's key team members:
- Sean McClain: Founder & CEO of AbSci and founder of 1 other company. Contact Info: 1 email address
View details of AbSci's Founder profiles and Board Members
AbSci's employee count trend
AbSci has 173 employees as of Apr 26. Here is AbSci's employee count trend over the years:
Uncover AbSci's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
AbSci's Competitors and alternates
Top competitors of AbSci include Antiverse, Adimab and Chai Discovery. Here is the list of Top 10 competitors of AbSci, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Antiverse 2017, Cardiff (United Kingdom), Series A | Developer of computational platform for de novo design of antibody therapeutics | $20M | 68/100 | |
2nd | Adimab 2007, Lebanon (United States), Series F | Antibody discovery and optimization platform for autoimmune and infectious diseases | $35.4M | 65/100 | |
3rd | Chai Discovery 2023, San Francisco (United States), Series B | Developer of artificial intelligence models for de novo molecular design | $230M | 65/100 | |
4th |  BigHat 2019, San Carlos (United States), Series B | Provider of antibody therapies developed by machine learning and synthetic biology | $148M | 63/100 | |
5th |  Oncimmune 2006, Cambridge (United States), Acquired | Immunodiagnostics company developing biomarker platforms for cancer and immune diseases | - | 58/100 | |
6th | AbSci 2011, Vancouver (United States), Public | Developer of AI based technology for the production of recombinant protein for therapeutic applications | $228M | 57/100 | |
7th | LabGenius Therapeutics 2012, London (United Kingdom), Series B | Developer of an automated platform for therapeutic antibody discovery | $69.5M | 55/100 | |
8th |  Laigo Biotechnology 2023, Utrecht (Netherlands), Seed | Developer of targeted protein degradation technology for therapeutic applications | $19.8M | 47/100 | |
9th |  Ordaos 2019, New York City (United States), Seed | Provider of an AI accelerator for biomedical research and drug discovery | $21.5M | 47/100 | |
10th | immunitoAI 2020, Bengaluru (India), Series A | Developer of AI-based platform for antibody discovery and therapeutics | $7.93M | 47/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on AbSci's competitors? Click here to see the top ones
AbSci's Investments and acquisitions
AbSci has acquired 2 companies including Totient and Denovium. AbSci has not made any investments as of now.News related to AbSci
Filter this listMedia has covered AbSci for a total of 14 events in the last 1 year, 8 of them have been about company updates and 2 about partnerships.
•
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 ResultsGlobeNewswire•Mar 24, 2026•AbSci
•
•
ARK Investment Management LLC Increases Stake in Absci Corporation $ABSIMarketBeat•Mar 05, 2026•AbSci, ARK Investment Management
•
Absci Reports New Data Showing ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell NicheGlobeNewswire•Dec 11, 2025•AbSci
•
Absci GAAP EPS of -$0.20 beats by $0.02, revenue of $0.38M misses by $1.2MSeeking Alpha•Nov 12, 2025•AbSci
•
Absci Corporation $ABSI Shares Sold by Pier 88 Investment Partners LLCMarketBeat•Nov 10, 2025•AbSci, Pier 88 Investment Partners
•
•
Absci Enhances AI Drug Discovery Through Oracle and AMD CollaborationBenzinga•Sep 11, 2025•AbSci, AMD, Oracle, Cohere
•
Absci Expands ABS-201 Scientific Advisory Board with Leading Dermatology ExpertsBenzinga•Aug 26, 2025•AbSci
•
Almirall and Absci Expand AI Drug Creation Collaboration with Second Dermatology TargetGlobeNewswire•Aug 07, 2025•AbSci, Almirall
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about AbSci
Explore our recently published companies
- Abhyudayainfra - India based, Unfunded company
- Rensaslb - Unfunded company
- Awning Consultants Abc - Unfunded company
- Jagpromotions - 2003 founded, Unfunded company
- Kritzermarketing - 1994 founded, Unfunded company
- Kullanatdunyasi - United Kingdom based, 2018 founded, Unfunded company
